about
Systematic review: Preventive and therapeutic applications of metformin in liver diseaseThe diverse roles of adiponectin in non-small-cell lung cancer: current data and future perspectives.Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes.Ovarian tumor-initiating cells display a flexible metabolismMetformin use and lung cancer risk in patients with diabetes.Use of noninsulin anti diabetics for prevention and treatment of cancer- narrative review article.Metformin: multi-faceted protection against cancer.Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis.Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again.Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.Metformin and Not Diabetes Influences the Survival of Resected Early Stage NSCLC Patients.Risk factors for cancer development in type 2 diabetes: A retrospective case-control studyDiabetes but not insulin is associated with higher colon cancer mortality.Colon cancer modulation by a diabetic environment: A single institutional experience.Metformin inhibits early stage diethylnitrosamine‑induced hepatocarcinogenesis in rats.Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning.Molecular pathways: adiponectin and leptin signaling in cancer.Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK.Liver MicroRNA-291b-3p Promotes Hepatic Lipogenesis through Negative Regulation of Adenosine 5'-Monophosphate (AMP)-activated Protein Kinase α1.Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients.Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes MellitusFuture directions in the prevention of prostate cancer.AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.Translation initiation in colorectal cancer.Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies.Is it time to test biguanide metformin in the treatment of melanoma?Inverse association between cancer and neurodegenerative disease: review of the epidemiologic and biological evidence.The role of stromal fibroblasts in lung carcinogenesis: A target for chemoprevention?Metformin: risk-benefit profile with a focus on cancer.Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies.Berberine Enhances Chemosensitivity and Induces Apoptosis Through Dose-orchestrated AMPK Signaling in Breast Cancer.Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In VivoMetformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.Control of Glycolytic Flux by AMP-Activated Protein Kinase in Tumor Cells Adapted to Low pHAssociation between metformin use and improved survival in patients with laryngeal squamous cell carcinoma.Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.Ginkgolic acid inhibits the invasiveness of colon cancer cells through AMPK activation.Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial.The role of clinical response to metformin in patients newly diagnosed with type 2 diabetes: a monotherapy study.A Cohort Study of Metformin and Colorectal Cancer Risk among Patients with Diabetes Mellitus.
P2860
Q28085535-5D216715-91AE-4D0A-97B9-3643BA0C33BAQ30984546-8E408531-B478-411D-ACA1-0BA81FF2ADDDQ34323510-6603883E-7C87-4FC4-8113-DAE74F7F6F15Q34658326-C448758E-AE67-4143-9934-D055C5AFFFFEQ35046673-6F021D01-FE2A-4BB3-8753-A0B222E1C47BQ35466765-E8B867EC-91DD-4C71-9028-C92BA3AF0D4FQ35764409-A2037BC6-C42D-44F2-8093-3D82D6FD6883Q35803926-3AA57E5E-B3FF-4385-B2D9-854124C24C90Q35915762-39F8FBDC-94CC-4FCE-A987-AE3B8F58555BQ36021012-E3AB6247-5F67-435B-BB59-22B547979577Q36131775-A7F52664-F354-434C-BAE5-00BA8242D0C4Q36159846-084D93D0-067C-4279-86DF-EF81AF0E3087Q36175076-4492C423-BD16-4047-BF89-90785E2E8FA6Q36295273-798366DB-42F6-482D-BF7E-F04309C90203Q36390358-1BC24AFC-27EB-4DF2-99C7-B9FDE7EB102FQ36524748-C281D3AE-0CE9-4FEF-BE92-BD1C4F673EA4Q36778002-76713E8B-325B-46F9-98A9-7C5CA941C5C7Q36861418-06B5CDA8-27C0-4D0C-81B1-715E8C8F3BF1Q36898227-F776E9B7-BE97-4D3A-AC98-B566808666D7Q37028124-E33E0BE8-D5C7-4EF7-A42D-982AB3E7C7DAQ37153221-1129DF6D-E30C-424E-9BEA-7813F198FE8DQ37279094-65BB698A-63F5-476F-98D7-A1D1E7F4448FQ37976243-EFB85E28-339B-4AA1-871C-07FB875C0121Q37993753-0457241A-32B0-473E-B97B-A6F6F72F0DEDQ38017727-B614AB3A-5DCE-4730-8CFC-FE54DF83F4FAQ38215034-D5D44F87-40ED-478A-B99B-7CBC8547C28EQ38239053-CCE393A1-CBC9-4DEB-9D21-B3540B18B767Q38328376-8A32ECA2-0EE1-4810-9831-E3FCDEEB9329Q38584636-66E950A5-0A5E-46EA-8635-4DDFD2C263B7Q39290525-1D0F28EF-7971-4ECF-B2E4-721A7965AD99Q41180271-AB415239-2DFF-4DE4-917A-F195B27BCD8BQ41285493-2939C2CB-2436-477E-87D1-3DAD39C65D19Q41388610-0BA9D384-73DB-47C6-A7F1-62145EF65871Q42127666-A1BB7110-F5C4-46D7-8B77-2F0FFC19E8B1Q43765815-ACBCC80A-151D-4C48-B713-135343E7DC17Q45909685-E97D9375-769D-4EF6-89C6-67D106F9EB2FQ47096456-0BF94A1D-5BB7-45FC-9B91-9A5F19FFCE0DQ47761912-A057DBB0-10CE-4FD6-8F5B-0A2E5FBEE740Q51323948-9E24F4C7-A596-4EEE-B68B-DB1B418E1220Q53282862-20328417-0133-4C5B-B8A3-FB5B94C51F49
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Metformin and neoplasia: implications and indications.
@en
Metformin and neoplasia: implications and indications.
@nl
type
label
Metformin and neoplasia: implications and indications.
@en
Metformin and neoplasia: implications and indications.
@nl
prefLabel
Metformin and neoplasia: implications and indications.
@en
Metformin and neoplasia: implications and indications.
@nl
P1476
Metformin and neoplasia: implications and indications.
@en
P2093
Ahmad Aljada
Shaker A Mousa
P304
P356
10.1016/J.PHARMTHERA.2011.09.004
P577
2011-09-06T00:00:00Z